Focus Partners Wealth
HRTX icon

Focus Partners Wealth’s Heron Therapeutics HRTX Stock Holding History

Focus Partners Wealth’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,514
Closed -$14K – 2864
2026
Q1 		$14K Sell
17,514
-130,956
-88% -$152K ﹤0.01% 2625
2025
Q4 		$3.57M Buy
148,470
+129,855
+698% +$160K ﹤0.01% 1084
2025
Q3 		$23.5K Buy
+18,615
New +$29.5K ﹤0.01% 2181
2025
Q1 		– Sell
-20,000
Closed -$30.6K – 1971
2024
Q4 		$30.6K Buy
+20,000
New +$32.4K ﹤0.01% 1837

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Focus Partners Wealth's HRTX Position: Q2 2026 in Review

Focus Partners Wealth sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 17,514 shares — an estimated $14K sold.

Focus Partners Wealth first reported a position in HRTX in Q4 2024 and held it in 4 quarters. The position peaked at $3.57M in Q4 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Focus Partners Wealth reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 17,514 Heron Therapeutics shares in Q2 2026, an estimated $14K.
  • Focus Partners Wealth first reported a position in Heron Therapeutics in Q4 2024 and held it in 4 quarters.
  • Focus Partners Wealth's Heron Therapeutics position peaked at $3.57M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.